GT Biopharma, Inc.
GTBPHealthcare|Biotechnology|US
$4.42
-0.12 (-2.64%)
DCF Value
$27.76
Tangible Book / Share
$2.30
Cash / Share
$3.19
Financials
Financial Snapshot
Market Cap
$5.6M
Enterprise Value
$618.7K
Revenue (TTM)
$0.00
Net Income (TTM)
-$22.1M
Cash & Investments
$5.0M
Net Cash
$5.0M
Free Cash Flow (TTM)
-$14.4M
Operating CF (TTM)
-$14.4M
Debt/Equity
0.00
Cash Runway & Burn Rate
Cash on Hand
$5.0M
Quarterly Burn
$3.6M
Monthly Burn
$1.2M
Est. Runway
~1.4 quarters
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $19.0K | $576.0K | $60.0K | $28.0K | $5.3M | $32.0M | $16.5M | $14.0M | $4.0M | $6.8M | $5.0M | |
| Operating Cash Flow | -$1.9M | -$5.4M | -$10.7M | -$3.7M | -$7.3M | -$15.6M | -$15.2M | -$8.9M | -$12.9M | -$12.9M | -$14.4M | |
| Free Cash Flow | -$1.9M | -$5.4M | -$10.7M | -$3.7M | -$7.3M | -$15.6M | -$15.2M | -$8.9M | -$12.9M | -$12.9M | -$14.4M | |
| Capital Expenditure | $0.00 | -$4.0K | -$36.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Financing Cash Flow | $1.9M | $6.0M | $10.2M | $3.4M | $12.5M | $42.3M | -$224.0K | $6.3M | $3.0M | $15.8M | $14.2M |
R&D Spending
R&D (TTM)
$3.5M
R&D Intensity
—
R&D Growth vs Prior
+0.2%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $975.0K | $1.1M | $9.1M | $1.7M | $485.0K | $9.6M | $8.8M | $6.5M | $5.8M | $3.5M | $3.5M | |
| SG&A | $8.4M | $134.5M | $12.5M | $9.8M | $6.3M | $47.9M | $12.4M | $7.1M | $8.6M | $8.9M | $12.8M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $1.0K | $2.0K | $7.0K | $4.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Gross Profit | -$1.0K | -$2.0K | -$7.0K | -$4.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D | $975.0K | $1.1M | $9.1M | $1.7M | $485.0K | $9.6M | $8.8M | $6.5M | $5.8M | $3.5M | $3.5M | |
| SG&A | $8.4M | $134.5M | $12.5M | $9.8M | $6.3M | $47.9M | $12.4M | $7.1M | $8.6M | $8.9M | $12.8M | |
| Operating Income | -$9.4M | -$135.6M | -$250.1M | -$11.5M | -$6.8M | -$57.5M | -$21.3M | -$13.6M | -$14.4M | -$12.4M | -$16.3M | |
| Interest Expense | $6.6M | $8.6M | $9.1M | $2.1M | $3.3M | $718.0K | $8.0K | $213.0K | $0.00 | $127.0K | $127.0K | |
| Pretax Income | $9.8M | -$144.2M | -$259.2M | -$38.6M | -$28.3M | -$58.0M | -$20.9M | -$7.6M | -$13.2M | -$28.4M | -$22.1M | |
| Net Income | $9.8M | -$144.2M | -$259.2M | -$38.6M | -$28.3M | -$58.0M | -$20.9M | -$7.6M | -$13.2M | -$28.4M | -$22.1M | |
| EPS (Diluted) | 1530000.00 | -3630.50 | -2192.50 | -285.50 | -161.25 | -51.50 | -16.50 | -141.00 | -173.50 | -156.25 | -104.00 | |
| EBITDA | -$9.4M | -$135.6M | -$250.1M | -$36.5M | -$25.0M | -$57.5M | -$21.0M | $6.0M | -$13.2M | -$28.2M | -$20.3M | |
| Shares Out. (M) | 0.00 | 0.04 | 0.12 | 0.14 | 0.18 | 1.13 | 1.27 | 0.05 | 0.08 | 0.22 | 1.55 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $19.0K | $576.0K | $60.0K | $28.0K | $5.3M | $9.0M | $5.7M | $1.1M | $4.0M | $6.8M | $5.0M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $23.0M | $10.8M | $12.9M | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $21.0K | $576.0K | $90.0K | $274.0K | $5.7M | $32.2M | $16.6M | $14.1M | $4.2M | $8.1M | $5.8M | |
| Total Assets | $25.0K | $254.4M | $25.4M | $396.0K | $5.7M | $32.2M | $16.7M | $14.1M | $4.2M | $8.1M | $5.8M | |
| Total Current Liabilities | $18.9M | $2.7M | $14.0M | $19.7M | $35.1M | $10.3M | $4.9M | $6.6M | $5.9M | $2.3M | $2.2M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $18.9M | $2.7M | $14.0M | $19.7M | $35.1M | $10.3M | $5.0M | $6.6M | $5.9M | $2.3M | $2.2M | |
| Stockholders' Equity | -$18.8M | $251.9M | $11.5M | -$19.1M | -$29.3M | $21.9M | $11.7M | $7.5M | -$1.7M | $5.8M | $3.6M | |
| Retained Earnings | -$124.6M | -$269.5M | -$528.7M | -$567.3M | -$595.6M | -$653.6M | -$674.5M | -$682.1M | -$695.2M | -$723.9M | -$731.4M |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$1.9M | -$5.4M | -$10.7M | -$3.7M | -$7.3M | -$15.6M | -$15.2M | -$8.9M | -$12.9M | -$12.9M | -$14.4M | |
| Capital Expenditure | $0.00 | -$4.0K | -$36.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Free Cash Flow | -$1.9M | -$5.4M | -$10.7M | -$3.7M | -$7.3M | -$15.6M | -$15.2M | -$8.9M | -$12.9M | -$12.9M | -$14.4M | |
| Investing Cash Flow | -$1.0K | -$4.0K | -$36.0K | $200.0K | $0.00 | -$23.0M | $12.1M | -$2.0M | $12.9M | $0.00 | $0.00 | |
| Financing Cash Flow | $1.9M | $6.0M | $10.2M | $3.4M | $12.5M | $42.3M | -$224.0K | $6.3M | $3.0M | $15.8M | $14.2M | |
| Issuance of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $24.7M | $0.00 | $6.3M | $3.0M | $16.0M | $14.1M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$224.0K | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $1.9M | $6.0M | $10.7M | $3.4M | $12.5M | $1.2M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $6.6M | $130.1M | $9.7M | $5.3M | $269.0K | $33.9M | $7.6M | $2.2M | $230.0K | $432.0K | $903.0K | |
| Net Change in Cash | -$28.0K | $557.0K | -$516.0K | -$32.0K | $5.3M | $3.7M | -$3.3M | -$4.6M | $3.0M | $2.9M | -$267.0K |
Dilution Tracker
Shares outstanding grew 25.7% over 5 years — significant dilution
Shares Outstanding
1M
5-Year Share Growth
+25.7%
Stock Issuance (TTM)
$14.1M
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.00 | 0.04 | 0.12 | 0.14 | 0.18 | 1.13 | 1.27 | 0.05 | 0.08 | 0.22 | 1.55 | |
| Change vs Prior % | — | 657516.7% | 199.6% | 14.6% | 29.5% | 542.1% | 13.2% | -95.8% | 40.7% | 190.6% | 604.1% | |
| Stock Issuance | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $24.7M | $0.00 | $6.3M | $3.0M | $16.0M | $14.1M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$224.0K | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $6.6M | $130.1M | $9.7M | $5.3M | $269.0K | $33.9M | $7.6M | $2.2M | $230.0K | $432.0K | $903.0K |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE % | -52.1% | -57.2% | -2246.2% | 201.9% | 96.7% | -264.8% | -178.0% | -101.6% | 788.1% | -490.0% | -443.1% | |
| ROA % | 39072.0% | -56.7% | -1020.5% | -9759.3% | -499.8% | -180.3% | -124.8% | -53.8% | -311.0% | -349.8% | -381.5% | |
| ROIC % | 144.0% | -53.9% | -1127.8% | 192.5% | 218.3% | -262.1% | -178.5% | -180.2% | 860.1% | -214.7% | -457.7% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | -100.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | -104.0% | -100.0% | -250.0% | 42.9% | 100.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Income | -5.0% | -1346.2% | -84.5% | 95.4% | 41.0% | -750.3% | 63.0% | 36.1% | -5.8% | 13.5% | |
| Net Income | 145.5% | -1576.0% | -79.8% | 85.1% | 26.8% | -105.0% | 64.0% | 63.6% | -73.3% | -115.4% | |
| EPS (Diluted) | 104.3% | -100.2% | 39.6% | 87.0% | 43.5% | 68.1% | 68.0% | -754.5% | -23.0% | 9.9% | |
| Operating Cash Flow | 58.6% | -181.3% | -96.6% | 65.7% | -98.5% | -114.9% | 2.5% | 41.8% | -45.8% | -0.1% | |
| Free Cash Flow | 58.6% | -181.6% | -97.1% | 65.8% | -98.5% | -114.9% | 2.5% | 41.8% | -45.8% | -0.1% | |
| R&D Expense | -2.5% | 9.5% | 749.0% | -81.6% | -70.9% | 1877.5% | -8.1% | -26.6% | -10.3% | -40.1% | |
| SG&A Expense | 5.6% | 1501.4% | -90.7% | -21.6% | -35.8% | 663.2% | -74.0% | -42.9% | 20.5% | 4.5% | |
| Total Assets | -53.7% | 1017372.0% | -90.0% | -98.4% | 1329.5% | 468.3% | -48.0% | -15.7% | -70.0% | 91.5% | |
| Book Value / Share | 93.8% | 100.2% | -98.5% | -248.3% | -17.7% | 111.6% | -52.7% | 1407.3% | -115.9% | 219.2% | |
| Debt | 27.4% | -99.8% | 34751.6% | 23.6% | 97.1% | -99.9% | 461.3% | -66.7% | -100.0% | 0.0% | |
| Diluted Shares | 500.0% | 657516.7% | 199.6% | 14.6% | 29.5% | 542.1% | 13.2% | -95.8% | 40.7% | 190.6% |
Valuation
P/E (TTM)At Loss
P/S0.00
P/B1.92
10Y Low / Med / High0.75 / 72.16 / 117.58
EV/EBITDAAt Loss
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$27.76
Tangible Book / Share
$2.30
Net Current Assets / Share
$2.83
Graham Net-Net
$1.77
Cash / Share
$3.19
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | 0.24 | -15.63 | -3.78 | -3.62 | -33.53 | -44.42 | -40.26 | -1.36 | -0.44 | -0.13 | -0.04 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | -0.12 | 8.89 | 84.89 | -7.31 | -32.40 | 117.58 | 72.16 | 1.38 | -3.46 | 0.75 | 1.92 | |
| EV/EBITDA | -1.56 | -16.51 | -3.96 | -4.19 | -38.81 | -44.67 | -40.13 | 1.55 | -0.14 | 0.09 | -0.03 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
-186.26
Distress
Piotroski F-Score
1
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $9.7M | $67.7M | $0.00 |
| Net Income | -$2.4M | -$1.8M | -$1.5M |
| EPS | $-10.75 | $-8.00 | $-7.00 |
| # Analysts (EPS) | 1 | 1 | 1 |